Cardiome/Astellas Kynapid Aiming For Limited Use, With New Trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Narrowing the indication for Cardiome/Astellas' Kynapid (vernakalant) alone was not enough to secure an approval for the atrial fibrillation therapy - Astellas will now run an additional Phase III clinical trial to prospectively study the narrower population that is the new target for approval: patients with recent onset a-fib who do not have a history of heart failure
You may also be interested in...
Merck Pumps Pipeline With $800M Cardiome Deal
FDA-delayed vernakalant for atrial fibrillation nets handsome pact, as more-lucrative oral form awaits Phase III trials.
Astellas/Cardiome’s Kynapid “Approvable”
FDA wants more safety data on IV vernakalant.
Kynapid Gets Panel Endorsement For Narrow Approval Due To Small Data Set
A restricted indication was strongly recommended by Cardiovascular and Renal Drugs Advisory Committee members to offset the uncertainty of adverse events with Astellas/Cardiome's Kynapid (vernakalant), especially since the atrial fibrillation product will likely be used in critical care situations like emergency rooms rather than by specialists